Introduction
Osteoarthritis (OA) represents a major health problem compounded by aging and increasingly obese populations and is the fasting growing cause of global disability 1 . Current treatments are focused on reducing symptoms, and there are few effective therapies. Most people with OA have persistent pain despite use of all prescribed therapies 1, 2 . Current pharmacological treatments are associated with significant toxicities and contra-indications, and their use is restricted across populations 1, 2 . There is therefore a major need to develop new analgesic therapies for OA. Polyacrylamide hydrogel (PAAG) (Contura International A/S, Soborg, Denmark) is a synthetic, non-degradable hydrogel, which is biocompatible and non-toxic 3 with water exchanging abilities 4 . The hydrogel has been used for years in the augmentation of soft tissues such as skin and bladder neck 5e9 , and histopathological studies of soft subcutaneous tissues from mice 3 , rats 5 , rabbits 6 , pigs 10 and humans 11 have shown that it supports cellular growth and integration, and possesses a permanent and stable augmentation effect due to the constant molecular water exchange with its host tissue 4 .
PAAG is also known for its ability to allow in-growth of host tissue cells in vivo. The tissue integration begins immediately after gel injection as a sort of foreign body reaction to the PAAG. Host macrophages and foreign-body giant cells initially surround the gel and then invade it. In the process these cells are gradually transformed into fibroblasts and endothelial cells, which eventually form a thin vessel-bearing fibrous network inside the gel 10 .
In a preliminary study, PAAG demonstrated analgesic benefits in equine OA joints up to 2 years post injection 12 . In order to understand any potential mechanism of action of PAAG, the first step would be to demonstrate if the gel was retained over the duration of purported benefit, and where the gel would be located following injection (joint cavity or tissues). The main purpose of this histopathological study was therefore to investigate the fate of the gel following injection, and the secondary aims were to determine the duration of retention and possible tissue distribution at different times after intra-articular injection of PAAG in normal and OA animal joints.
Methods
Two animal joint types were examined. Firstly, we conducted a prospective, longitudinal, controlled study on normal knee joints in rabbits, and secondly, a post mortem examination was made on OA horse joints which had been treated with PAAG at different times prior to death. The PAAG used in all these cases was Aquamid Reconstruction ® (Contura International A/S, Soeborg, Denmark).
Ethical approval was obtained from the Danish Animal Welfare Organization (dyreforsøgstilsynet, reference J.nr. 2010/561-1774).
Prospective comparative study in normal rabbit joints A total of 10 two-year old New Zealand white rabbits were used. The first four received injections in the right knee with 2.5% PAAG and in the left knee saline as control. The remaining six rabbits also received PAAG injections in the right knee but in the left knee they received hyaluronic acid gel (HAG, Durolane 20 mg/ml, Galderma, Switzerland) as a control. The volume of injected PAAG, saline or HAG was 0.3 ml per knee. This was administered after having removed a few drops of joint fluid to ensure correct position of the injection needle. The rabbits were observed daily for well-being and their weight was measured once a week and they were kept under standard conditions in pairs. The first four rabbits (saline control group) were sacrificed after 10 days. The remaining six rabbits were sacrificed, two at a time, after 3, 6 and 12 months. For all 10 rabbits both knee joints were removed and inspected macroscopically. All synovial, cartilage, tendon and fatty tissue of the joint was removed and processed for histopathological examination using H&E and van Gieson/Alcian blue stains as tissue markers.
A study of osteoarthritic joints in the horse
This study included seven horses (age 5e13 years, median 10 years) presenting a total of 13 joints with veterinarian-diagnosed OA that had been treated with PAAG. Five joints without OA served as controls. The horses were part of a large prospective clinical study carried out at three different equine centers, where 1e4 (mean 2) ml of PAAG had been injected per joint and where the effect of the treatment was followed postoperatively for up to 2 years 12 . Histopathological examination was carried out on leg joints from horses having died during that period. Treatment with PAAG had been performed from 7 days to 2 years previously. All horses had been euthanized for causes unrelated to the PAAG treatment. After dissection and macroscopic inspection of the joints, all synovial tissue representing the inner capsule was routinely fixed, paraffin embedded and stained for light microscopy. Samples from the cartilage were also examined (two from each joint).
Results

Rabbit study
The rabbits with normal joints were all healthy at injection and remained so during the study with no change in joint movement (e.g., activity restriction or limping) at any time.
On gross inspection there were no differences other than two cases of slight capsule hemorrhage at injection site. Upon opening the joint cavity, the synovial fluid was more viscous, and the inner synovial lining appeared slightly thickened on the PAAG-treated side as compared to the saline-treated side at day 10. No macroscopic differences could be discerned between PAAG and HAG treated joints at any time point.
Light microscopy on the PAAG treated side at day 10 showed a synovial lining layer which was 5e10-fold thicker than on the saline injected side, due to the gel containing proliferating synovial cells [ Fig. 1(a) and (b) ].
At 3, 6 and 12 months the synovial layer was still up to 10-times thickened on the PAAG treated side [ Fig. 1(c) ], and the synovial lining was present on top of the gel facing the cavity [ Fig. 1(c) ]. By now only scattered synovial cells were seen inside the gel intermixed with a fine fibrous network. PAAG was no longer seen within the cavity, but on the HAG treated side a minimal amount of a dense homogenous blue material thought to be a remnant trace of Durolane was seen at 3 months in one of the synovial foldings [ Fig. 1(d) ]. This was not seen at 6 and 12 months.
Horse study Macroscopic findings
Coffin, fetlock and knee joints had been treated with PAAG. Three untreated coffin joints and two fetlock joints served as controls. Upon opening the joint cavity, various grades of osteophyte formation and/or cartilage defect(s) could only be seen in three of the five treated fetlock joints. The PAAG appeared as a thick, smooth, glistening, yellow substance or in the coffin joint as small clear deposits along the inner part of the anterior longitudinal tendon facing the cavity. Free PAAG inside the cavity could not be discerned from joint fluid on naked eye inspection.
Light microscopy findings
In the short term, 1 and 2 weeks post treatment, the PAAG appeared as an inner layer within the synovial lining intermixed with proliferating synovial cells, similar to the histology seen in the rabbit model. At 1 month the synovial cells had apparently relocated towards the surface, and at 3 months a distinct layer of synovial cells had formed on top of the integrated PAAG [ Fig. 2(a) ]. The same pattern was found at 8 months and at 24 months [ Fig. 2(c)  and (d) ]. In general, there was no reduction in membrane thickness of the integrated gel, and at higher magnification, it could be seen by H&E morphology that the PAAG had materialized itself as a thick integrated zone with at first scattered mononuclear inflammatory cells, possibly synovial cells [ Fig. 2(a) ], and later with a fine fibrous network and very few of these inflammatory cells [ Fig. 2(d) ].
Discussion
This histopathological study investigating the location and retention of PAAG in joints with and without OA has revealed that PAAG appears to form a sub-lining layer. All examined joints from both species showed the same PAAG integration into the inner layer of the synovium and the re-location of the synovial cells on the surface. Furthermore, we found that integrated PAAG was unaltered after at least 2 years. The subsynovial zone retained its thickness.
The main differences between the integration of PAAG in previous tissues and the synovial membrane of the present study is that the previous studies were not associated with any luminal surfaces and the gel contained macrophages and giant cells up until 14 months post injection 10 . The current study uniquely demonstrated the formation of a novel synovial lining layer after integration of the PAAG, and no giant cells at any time [ Figs. 1(a) , (c) and
Analgesic benefits for PAAG have been reported in an observational study in the horse, where one treatment of 2 ml PAAG in fetlock or carpus joints was found to have a significant effect on lameness and effusion during the first month post treatment, after which this effect increased progressively until 6 months, and then stabilized up until 24 months 12 . Recently an observational pilot study of 60 human knees with OA, which were treated with nondegradable PAAG, showed promising results for pain reduction 13 .
It is interesting to speculate on potential mechanisms by which PAAG may produce an analgesic effect, and the effects of the sublining layer of PAAG are not clear from this work. There may be changes to synovial cell composition or cytokine production, and/ or mechanical properties of the synovium. This will require further investigation, as this study has several limitations including a limited number of experimental animals, different types of horse joints, variations in PAAG doses and different time periods of follow up.
In conclusion, intra-articular PAAG is present in joint synovium and persists over a time course consistent with reported analgesic benefits in observational animal and human studies. In parallel with ongoing clinical studies of efficacy, further studies are needed to explain its potential mechanism of action.
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